Invivyd announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer, effective immediately, while the Board institutes a search for a permanent CEO. Gowler succeeds Dave Hering. “The Invivyd Board of Directors is positioning the company for its next phase of growth,” said Marc Elia, Chairperson. “Invivyd is poised to lead a brand-new paradigm in delivering novel, impactful monoclonal antibody therapies for the pre-exposure prophylaxis of COVID-19, and we wish to fully unlock this capability and associated value creation. In the interim, we are pleased to align the day-to-day leadership of the company with Jeremy, who is primarily responsible for our commercial execution, and I personally look forward to partnering with him on the success of the company.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd upgraded to Buy from Neutral at Guggenheim
- Invivyd gets EUA from FDA for Pemgarda in COVID-19 in adults and adolescents
- Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
- Invivyd (NASDAQ:IVVD): Innovative COVID Treatment but a Speculative Investment
- Invivyd’s Financial Stability Hangs in the Balance as HHS Reviews PEMGARDA’s Emergency Use Authorization
